45 - Hot Topics in Pediatric Infectious Diseases

Thursday, September 30, 2021

5:15 PM - 6:30 PM EDT

Interactive Moderator(s)

William Steinbach, MD

Vice Chair of Research, Department of Pediatrics
Pediatric Infectious Diseases
Duke University
Durham, NC, United States

Sfunga (Individual(s) Involved: Self): Advisor or Review Panel member

Panelist(s)

Joshua Wolf, MBBS, PhD, FRACP

Associate member
St. Jude’s Children’s Research Hospital
Memphis, TN, United States

I do not have any relevant financial / non-financial relationships with any proprietary interests.
Brian Fisher, DO, MPH, MSCE

Associate Chair of Research
Children's Hospital of Philadelphia
Philadelphia, PA, United States

Astellas (Individual(s) Involved: Self): Advisor or Review Panel member; Merck (Individual(s) Involved: Self): Grant/Research Support; Pfizer (Individual(s) Involved: Self): Grant/Research Support
Tony Moody, MD

Professor of Pediatrics and Immunology
Duke University
Durham, NC, United States

Abcam (Individual(s) Involved: Self): Advisor or Review Panel member; Grid Therapeutics (Individual(s) Involved: Self): co-founder, Other Financial or Material Support, Shareholder; GSK (Individual(s) Involved: Self): Advisor or Review Panel member

Participants should be aware of the following financial/non-financial relationships:

William J. Steinbach, MD: Sfunga (Individual(s) Involved: Self): Advisor or Review Panel member

Joshua Wolf, MBBS, PhD, FRACP: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Brian Fisher, DO, MPH, MSCE: Astellas (Individual(s) Involved: Self): Advisor or Review Panel member; Merck (Individual(s) Involved: Self): Grant/Research Support; Pfizer (Individual(s) Involved: Self): Grant/Research Support

Tony Moody, MD: Abcam (Individual(s) Involved: Self): Advisor or Review Panel member; Grid Therapeutics (Individual(s) Involved: Self): co-founder, Other Financial or Material Support, Shareholder; GSK (Individual(s) Involved: Self): Advisor or Review Panel member

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
ACPE Credits: ACPE 1.25 Knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-0000-21-001-H01-P

Learning Objectives:

At the conclusion of this session, participants will be able to:

define new strategies for MDR GNR infections
define novel antifungal paradigms for candideia
define the next respiratory viral pandemic